Lupin announced that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). These validations cover all three emission scopes �V Scope 1, Scope 2, and Scope 3 - aligning with the Paris Agreement to limit global temperature rise to 1.5�XC. This milestone underscores Lupin��s commitment to sustainability and decisive climate action, positioning the company among a select group that has achieved comprehensive SBTi validation within a year of setting its climate targets. Key short-term targets: �h - Reduce absolute Scope 1 and 2 greenhouse gas emissions by 42.0% by FY 2030, with FY 2023 as the base year. �h - Reduce Scope 3 greenhouse gas emissions by 61.07% by FY 2033, across purchased goods and services, fuel- and energy-related activities, upstream and downstream transportation and distribution, business travel, employee commuting, processing and use of sold products, and franchises, using FY 2024 as the baseline.These goals are aligned with the 1.5�XC pathway and validated under SBTi��s latest guidelines, thereby positioning Lupin as a key participant in the global effort to combat climate change. Powered by Capital Market - Live News

Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin, today announced a long-term strategic alliance with PolyPeptide Group AG (PolyPeptide) (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients. This collaboration aims to enhance supply chain resilience, improve operational efficiency, and accelerate readiness for the rapidly expanding global peptides market. It also advances next-generation peptide therapeutics, including those for metabolics, supporting the long-term strategic growth of both organizations.As part of the alliance, both companies will work towards the following: �h Expanding sourcing options and fortifying peptide supply chains to meet rising global demand for peptide APIs, including for metabolic disease therapies. �h Integrating procurement and supply planning �h Ensuring unwavering quality and reliability and delivering superior service globally This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets, while enhancing PolyPeptide��s position as a trusted CDMO partner.  Powered by Capital Market - Live News

Lupin today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Siponimod Tablets, 0.25 mg, 1 mg and 2 mg. This product would be manufactured at Lupin`s Pithampur facility in India.Siponimod Tablets, 0.25 mg, 1 mg and 2 mg are bioequivalent to Mayzent� Tablets, 0.25 mg, 1 mg and 2 mg of Novartis Pharmaceuticals Corporation, and indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults. Siponimod Tablets (RLD Mayzent�) had estimated annual sales of USD 195 million in the U.S. (IQVIA MAT October 2025). Powered by Capital Market - Live News

Lupin as entered into an Exclusive Licensing Agreement with Valorum Biologics (Valorum), a biosimilar specialist in the U.S., for its biosimilar Armlupeg� (pegfilgrastim-unne).Under the terms of the agreement, Valorum will advance the commercialization and distribution of Armlupeg� (pegfilgrastim-unne) in the United States. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront license fee and a royalty payment on net sales. Pegfilgrastim-unne is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy. Powered by Capital Market - Live News

Lupin announced that the United States Food and Drug Administration (U.S. FDA) has approved Armlupeg� (pegfilgrastim-unne) 6 mg/0.6 mL injection for subcutaneous use in a single-dose prefilled syringe, as biosimilar to Neulasta� (pegfilgrastim) 6 mg/0.6 mL injection. The product will be manufactured at Lupin`s Biotech facility in Pune, which was inspected by the U.S. FDA prior to approval. Armlupeg� is indicated for:  - Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.  - Increase survival in patients acutely exposed to myelosuppressive doses of radiation. Powered by Capital Market - Live News